SELL with 50-60% trim from current weight, targeting 40-50% of benchmark exposure; staged re-entry only on confirmed multi-day technical recovery

• 60% earnings delivery on a name priced for 58% growth represents a thesis break, not a survivable outcome—market would reprice multiple and growth rate simultaneously
• Current 60-75% of benchmark exposure (3-3.75% single-stock concentration) is too large given deteriorating technicals, stretched valuation, and active policy risk
• Re-entry trigger at 1,222-1,224 is too loose—one close above 10 EMA/VWMA is noise in a 3.5% ATR name rather than confirmed reversal
• 1,288 prior-high cap is irrelevant in trim context; conflates sell and buy-back decisions that should be managed separately
• Institutional crowding creates setup for sharp, violent reversals when data turns; 87% rate-cut bets off table and PCE re-accelerating are negative signals
• No rate cuts = no multiple expansion tailwind; entire case rests on flawless 58% earnings growth execution with 31-35x multiple on slowing growth historically a poor entry
• Zepbound cost-savings study excluded drug costs themselves—this is the economic argument for payer reimbursement, not a minor methodology footnote

→ vs aggressive: Earnings math framing is flawed; 60% delivery on 58% growth priced name is a thesis break, not a clean TTM reversion—expect overshoot to downside in narrative unwind, not orderly repricing

→ vs aggressive: Position sizing of 60-75% of benchmark leaves 3-3.75% single-stock exposure—too concentrated for asymmetric risk profile where downside exceeds upside

→ vs aggressive: Re-entry trigger of single close above 1,224 is insufficient; conservative framework requires multi-day hold, MACD histogram flip to positive, RSI back above 55, and volume confirmation

→ vs aggressive: Underestimates macro concession—no rate cuts removes multiple expansion tailwind entirely, placing full burden on earnings execution

→ vs aggressive: Underweights institutional crowding risk; sparse retail discussion does not mean story is undiscovered—it means marginal flow faces fully-positioned sophisticated holders when data turns

→ vs aggressive: Treats drug pricing risk as known and priced when Zepbound study methodology (excluding drug costs) undermines payer reimbursement thesis at a politically opportune time

SELL — trim 35-45% into $1,215-$1,223 resistance zone, retain approximately 50-60% of benchmark weight, require multi-day confirmation above $1,224 with MACD histogram positive and RSI above 50 before re-engaging, stage re-entry into thirds with final third only on breakout above $1,288

• Agrees with SELL direction from both sides but proposes 35-45% trim as middle ground between aggressive analyst (25-40% trim, 60-75% retained) and conservative analyst (50-60% trim, 40-50% retained)
• Elite fundamentals intact: 44.7% revenue growth, 95% net income growth, 54.2% operating margins, 102.3% ROE, 0.506 beta
• Technical deterioration evident: fresh MACD bearish cross, 50 SMA test underway, 1,222-1,224 zone flipped from support to resistance
• Re-entry framework requires multi-day confirmation (at least 2-3 consecutive closes above $1,224), MACD histogram positive, RSI back above 50, and volume confirmation
• Staged re-entry in thirds: first third on confirmed multi-day reclaim above $1,224, second third on stronger momentum confirmation, final third only on breakout above $1,288 supply zone
• Premium valuation concern: 25.2x forward P/E multiple with 87% market-implied odds of no 2026 rate cuts removing multiple-expansion tailwind
• Pipeline catalysts remain live: Foundayo EU ramp, BioArctic Alzheimer's deal, Zepbound RWE data, retatrutide Phase 3 potential; full exit means missing these
• Institutional crowding risk: sentiment at 7/10 bullish with Ken Griffin quadrupled stake suggests marginal buyer faces crowded positioning

→ vs aggressive: Re-entry trigger of single close above 1,222-1,224 is too loose in a 3.5% ATR name — one close is noise not confirmed reversal; also underestimates institutional crowding risk when smart money already positioned

→ vs conservative: 50-60% trim to 40-50% retained overweights downside probability and underweights fundamental quality and pipeline depth; LLY beta of 0.506 historically more defensive in drawdowns than typical growth names; company fundamentals (GLP-1 dominance, manufacturing scale-up, pipeline depth) warrant more exposure than conservative proposes

→ vs aggressive: Mistakes company quality as reason to stay heavily long rather than sizing position appropriately to elevated premium valuation and technical deterioration